FDA-Approved MedicationUpdated October 2026

Rybelsus Guide

Rybelsus is semaglutide in a once-daily tablet, the first GLP-1 receptor agonist approved in oral form (September 20, 2019), for adults with type 2 diabetes. In the US it is being discontinued: on June 4, 2026 the FDA listed the 3 mg, 7 mg and 14 mg tablets as discontinued, to be replaced by Ozempic tablets, a reformulated version of the same medicine in 1.5 mg, 4 mg and 9 mg strengths that went on sale on May 4, 2026. Pharmacies may still dispense remaining Rybelsus stock, and Novo Nordisk says Rybelsus will still be sold outside the US. Both names share one FDA label, and the label warns they are not substitutable milligram for milligram: Rybelsus 7 mg corresponds to Ozempic tablets 4 mg, and 14 mg to 9 mg. The molecule is the one in injectable Ozempic and Wegovy, combined with an absorption enhancer (SNAC) that lets the peptide cross the stomach lining.

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

By Ruth Calder · Enforcement Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed

At a Glance

Rybelsus at a glance
Generic NameSemaglutide
Brand NamesRybelsus
FDA StatusFDA-approved September 20, 2019 for blood sugar control in adults with type 2 diabetes; also approved to lower the risk of major cardiovascular events in adults with type 2 diabetes at high risk. Discontinued in the US: the FDA listed Rybelsus 3 mg, 7 mg and 14 mg as discontinued on June 4, 2026, to be replaced by Ozempic tablets (1.5 mg, 4 mg, 9 mg) on the same label. Not approved for weight loss. The oral semaglutide approved for weight reduction is the Wegovy tablet, which includes a 25 mg dose; Ozempic tablets have no 25 mg strength.[1]
Approval DateSeptember 20, 2019[1]

In the US, Rybelsus is being replaced by Ozempic tablets, which come in different strengths (1.5, 4 and 9 mg, against Rybelsus's 3, 7 and 14 mg). Our guide to Ozempic tablets covers the dosing, the fasting rule and the self-pay price.

How does Rybelsus work?

Rybelsus delivers semaglutide — a GLP-1 receptor agonist — in tablet form by co-formulating each pill with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC), an absorption enhancer that transiently raises gastric pH and helps the semaglutide peptide cross the gastric mucosa intact before stomach acid and proteases can degrade it. After absorption the mechanism is the injectable one exactly: GLP-1 receptors switch on, insulin secretion rises in a glucose-dependent way, glucagon is suppressed, the stomach empties more slowly and appetite falls. What differs is the handling. The SNAC–semaglutide complex is fragile, so the stomach has to be empty, the tablet goes down with 4 oz of plain water at most, and nothing else — no food, no other drink, no other oral medication — for a minimum of 30 minutes afterwards. Break that and absorption falls off sharply.[2][3]

Dosing Schedule — Rybelsus (being discontinued)

Rybelsus uses a gradual dose escalation to minimize side effects. Always follow your prescriber's guidance and the current FDA label[1].

Days 1–303 mg orally once daily (starter dose; not effective for glycemic control)
Days 31–607 mg orally once daily
Day 61 onward, if more glycemic control is needed14 mg orally once daily (maximum dose)

Dosing Schedule — Ozempic tablets (replacement)

Days 1–301.5 mg orally once daily (starter dose)
Days 31–604 mg orally once daily (label match for Rybelsus 7 mg)
Day 61 onward, if more glycemic control is needed9 mg orally once daily (label match for Rybelsus 14 mg)

What side effects does Rybelsus cause?

Common: nausea, abdominal pain, diarrhea, decreased appetite, vomiting, constipation. Nausea is most frequent during dose escalation and typically diminishes within 4–8 weeks at a stable dose. Serious (rare): pancreatitis, diabetic retinopathy complications in T2D patients, acute kidney injury (often related to dehydration from GI side effects), gallbladder disease, hypoglycemia when combined with insulin or sulfonylureas, hypersensitivity reactions. Boxed warning: thyroid C-cell tumors observed in rodent studies — contraindicated in patients with personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).[1][2]

Nothing above is the full list. Your prescriber can give you the complete safety picture, and every adverse reaction on record sits in the current FDA prescribing information[1].

Clinical Trial Results

Rybelsus was approved on the PIONEER program of randomized trials in adults with type 2 diabetes. In PIONEER 1 (Aroda and colleagues, Diabetes Care 2019, PMID 31186300), 26 weeks of 14 mg monotherapy lowered HbA1c by 1.4 points against 0.3 on placebo; the label reports a mean weight change of −3.7 kg on 14 mg against −1.4 kg on placebo, and the published abstract puts the placebo-adjusted difference at −2.3 kg. In PIONEER 4 (Pratley and colleagues, Lancet 2019, PMID 31186120), oral semaglutide 14 mg was noninferior to liraglutide 1.8 mg injections for HbA1c at week 26 (−1.2% vs −1.1%) and lowered weight more (−4.4 kg vs −3.1 kg). PIONEER 6 (Husain and colleagues, NEJM 2019, PMID 31185157) enrolled 3,183 patients at high cardiovascular risk and showed the tablet did not raise cardiovascular risk (HR 0.79, 95% CI 0.57 to 1.11). SOUL (McGuire and colleagues, NEJM 2025, PMID 40162642) randomized 9,650 patients to 14 mg or placebo and found fewer major cardiovascular events on the tablet (12.0% vs 13.8%, HR 0.86), which added the heart indication. OASIS 1 (Knop and colleagues, Lancet 2023, PMID 37385278) tested a 50 mg dose in 667 adults without diabetes (15.1% weight loss vs 2.4% on placebo at 68 weeks); that dose is not an approved product.[2]

Source: Published clinical trial data (STEP / SURMOUNT trial series) — see the Sources panel below for full citations.

Where can you get Rybelsus?

Sellers in our register that will dispense semaglutide, or a compounded version of it, after an online consultation — shipped to your door.

7.8/ 10

Vital Edge

Best for: moving between compounded and brand without changing seller

★★★★☆7.8/10

Editorial score · methodology

$645/mo
BrandSemaglutideLegitScript Verified
Get StartedRead full Vital Edge review →

1 seller in the register publishes a price; the lowest starts at $645 a month, checked October 2026. What each one charges to start, cheapest at the top. Compounded semaglutide from state-licensed 503A pharmacies is legal under federal compounding law when made for an individual patient[4], and the rules loosen further, to include bulk compounding by 503B outsourcing facilities, only while a molecule sits on the FDA Drug Shortage List[5]. An FSA or HSA will generally cover either kind of prescription, compounded or branded, under IRS Publication 502[6]. What you actually pay moves with your dose and with whatever promotion happens to be running.

Starting Rybelsus price per seller, cheapest first. Prices in USD per month; checked October 2026.
ProviderStarting PriceLink
Vital Edge$645/moVisit

Short verdict pages setting Rybelsus against the other GLP-1 options, working from the trial results, the dose ladders on each label, and what the manufacturers charge today.

See all drug-vs-drug verdicts.

The trials that produced the Rybelsus label, taken endpoint by endpoint, with the figures read off the source.

Questions people actually asked about Rybelsus in named subreddits, each answered from the published trial data.

Longer pieces written here, built on the trial papers themselves, checked against the FDA label, and argued rather than summarized.

503A vs 503B Compounding Pharmacies: Who Oversees Your Compounded GLP-1
A 503A pharmacy compounds per patient under a state board. A 503B outsourcing facility registers with FDA, follows CGMP, is inspected and must report adverse events. What each means for compounded GLP-1s, and how to check yours.
10 min read12 citations
The Head-to-Head, and What It Settles
751 adults randomized to tirzepatide or semaglutide, each at maximum tolerated dose, for 72 weeks. Tirzepatide produced 20.2% weight loss against 13.7%, and on several other endpoints the answer runs the other way.
7 min read3 citations
Many People Never Reach the Dose
Only 58% of people starting semaglutide reached the recommended maintenance dose after four weeks, and 21% stayed on the starting dose. More than half of oral semaglutide starters stopped altogether.
6 min read1 citation
Switching Between GLP-1 Drugs
No label contains a dose equivalence between semaglutide and tirzepatide, because no regulator has been asked to approve one. Every conversion chart online is somebody's arithmetic.
5 min read3 citations
Does Your GLP-1 Wear Off Before the Next Dose?
Half of each dose is still present when the next one is due. The label puts semaglutide's elimination half-life at roughly seven days, tirzepatide's at about five. That is a slope, not a cliff.
6 min read2 citations
GLP-1 Drugs and Type 1 Diabetes: The Label Says Unevaluated. Three Trials Disagree.
36% of people with type 1 diabetes and obesity hit a composite of time-in-range, low-glucose safety and 5% weight loss, against 0% on placebo. Total daily insulin fell about a third in a second trial.
7 min read9 citations

Frequently Asked Questions

FDA-approved September 20, 2019 for blood sugar control in adults with type 2 diabetes; also approved to lower the risk of major cardiovascular events in adults with type 2 diabetes at high risk. Discontinued in the US: the FDA listed Rybelsus 3 mg, 7 mg and 14 mg as discontinued on June 4, 2026, to be replaced by Ozempic tablets (1.5 mg, 4 mg, 9 mg) on the same label. Not approved for weight loss. The oral semaglutide approved for weight reduction is the Wegovy tablet, which includes a 25 mg dose; Ozempic tablets have no 25 mg strength.
What you pay for Rybelsus turns on who is selling it and in what form. Uninsured, the branded product runs roughly $1,000 to $1,600 a month; compounded versions through telehealth sellers usually land between $129 and $400. The table above carries the current figures from our register. Before you commit, check whether a manufacturer savings program applies to you.
Common: nausea, abdominal pain, diarrhea, decreased appetite, vomiting, constipation. Nausea is most frequent during dose escalation and typically diminishes within 4–8 weeks at a stable dose. Serious (rare): pancreatitis, diabetic retinopathy complications in T2D patients, acute kidney injury (often related to dehydration from GI side effects), gallbladder disease, hypoglycemia when combined with insulin or sulfonylureas, hypersensitivity reactions. Boxed warning: thyroid C-cell tumors observed in rodent studies — contraindicated in patients with personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Rybelsus is prescription-only, so someone licensed has to write it — your own doctor, an endocrinologist, or one of the telehealth sellers above. For compounded versions the telehealth route is usually both quicker and cheaper out of pocket than a traditional pharmacy.
Sources & methodology — as of November 2026
  1. 1.FDA — Rybelsus (oral semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
  2. 2.OASIS 1 Trial — Oral Semaglutide 50 mg for the Treatment of Adults with Overweight or Obesity (Knop FK et al.)— The Lancet.PMID: 37385278.
  3. 3.ADA — Standards of Care in Diabetes (2025)— American Diabetes Association.
  4. 4.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
  5. 5.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
  6. 6.IRS Publication 502 — Medical and Dental Expenses (HSA/FSA eligibility)— Internal Revenue Service.